ATYR (aTyr Pharma) Tariff Resilience Score: 7/10 (As of Jun. 29, 2026)


ATYR aTyr Pharma Inc ATYR
14 GF Score
Price $0.55
GF Value $0.46
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is aTyr Pharma Tariff Resilience Score?

aTyr Pharma ATYR -0.83% 14 Tariff Resilience Score is 7 as of Jun. 29, 2026. GuruFocus rates ATYR with a GF Score™ of 14/100 and a GF Value™ of $0.46 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,375 Biotechnology companies, aTyr Pharma ranks better than 90.4% on this metric.

aTyr Pharma has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

aTyr Pharma has Moderate resilience with primary operations in the US. Limited international supply chain exposure. Historical tariff changes have minimal impact. Strong domestic focus and potential for alternative suppliers.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes aTyr Pharma might have Highly Resilient.

aTyr Pharma  (NAS:ATYR) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

aTyr Pharma Tariff Resilience Score Related Terms

ATYR vs DWTX, CNTX, INKT: Tariff Resilience Score Comparison

For the Biotechnology subindustry, aTyr Pharma's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

aTyr Pharma Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, aTyr Pharma's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where aTyr Pharma's Tariff Resilience Score falls into.


ATYR
14GF Score
aTyr Pharma Inc ATYR
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
aTyr Pharma (ATYR) has a Tariff Resilience Score of 7 as of Jun. 29, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, aTyr Pharma ranks #132 out of 1375 companies in the Biotechnology industry, placing it in the top 9.6%.
Is aTyr Pharma's Tariff Resilience Score too high?
aTyr Pharma's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. aTyr Pharma's value of 7 is 75% above this industry median. Based on the distribution chart, aTyr Pharma ranks #132 out of 1375 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, aTyr Pharma has a GF Score™ of 14/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does aTyr Pharma's Tariff Resilience Score compare to DWTX and CNTX?
According to the Biotechnology industry distribution chart, aTyr Pharma ranks #132 out of 1375 companies for Tariff Resilience Score. This places aTyr Pharma in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. aTyr Pharma's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,375 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. aTyr Pharma's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. aTyr Pharma's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is aTyr Pharma stock overvalued right now?
Based on GuruFocus' analysis, aTyr Pharma (ATYR) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.46, compared to a current price of $0.55 — trading 19.7% above its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. aTyr Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For aTyr Pharma (ATYR), the current Tariff Resilience Score is 7 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is aTyr Pharma (ATYR) Overvalued in 2026?

Based on GuruFocus' analysis, aTyr Pharma stock appears to be overvalued. The current stock price of $0.55 is trading 19.7% above its estimated GF Value™ of $0.46. GuruFocus considers aTyr Pharma to be Modestly Overvalued.

Key valuation signals for ATYR:

  • Tariff Resilience Score: 7
  • GF Value™: $0.46 vs. price of $0.55 (19.7% above fair value)
  • GF Score™: 14/100 with 4 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1375)

No single metric tells the full story. See the ATYR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

aTyr Pharma Business Description

Other Exchanges 471A:Germany
Address 10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
14GF Score

Get the complete analysis for ATYR

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.55
Price
$0.46
GF Value